Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study

BACKGROUND: Portal hypertension is a severe complication of cirrhosis. This Phase Ib study (NCT03842761) assessed the safety, tolerability, and pharmacokinetics of soluble guanylyl cyclase activator BI 685509 in patients with mild or moderate hepatic impairment (Child–Pugh [CP] A or B cirrhosis) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawitz, Eric J., Reiberger, Thomas, Schattenberg, Jörn M., Schoelch, Corinna, Coxson, Harvey O., Wong, Diane, Ertle, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615399/
https://www.ncbi.nlm.nih.gov/pubmed/37889522
http://dx.doi.org/10.1097/HC9.0000000000000276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615399/
https://www.ncbi.nlm.nih.gov/pubmed/37889522
http://dx.doi.org/10.1097/HC9.0000000000000276

Ejemplares similares